Leerink Partnrs Reduces Earnings Estimates for CVS Health

CVS Health Co. (NYSE:CVS - Free Report) - Analysts at Leerink Partnrs reduced their Q2 2025 earnings per share (EPS) estimates for CVS Health in a report released on Thursday, April 24th. Leerink Partnrs analyst M. Cherny now forecasts that the pharmacy operator will earn $1.54 per share for the quarter, down from their prior forecast of $1.61. Leerink Partnrs has a "Strong-Buy" rating on the stock. The consensus estimate for CVS Health's current full-year earnings is $5.89 per share. Leerink Partnrs also issued estimates for CVS Health's Q4 2025 earnings at $1.35 EPS.

Other analysts have also recently issued research reports about the company. JPMorgan Chase & Co. lifted their price target on CVS Health from $80.00 to $81.00 and gave the company an "overweight" rating in a report on Tuesday, February 18th. Piper Sandler upped their price target on CVS Health from $72.00 to $74.00 and gave the stock an "overweight" rating in a report on Friday, March 21st. Truist Financial raised their price objective on CVS Health from $76.00 to $82.00 and gave the company a "buy" rating in a research note on Friday, April 11th. Wells Fargo & Company lifted their price target on CVS Health from $68.00 to $73.00 and gave the stock an "overweight" rating in a research note on Thursday, February 13th. Finally, Barclays increased their target price on shares of CVS Health from $71.00 to $73.00 and gave the stock an "overweight" rating in a report on Thursday, February 13th. Four investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $71.83.

CVS Health Trading Up 2.5 %

Shares of NYSE:CVS traded up $1.62 during trading on Monday, reaching $66.65. The stock had a trading volume of 12,520,454 shares, compared to its average volume of 11,838,905. The business has a fifty day moving average price of $66.45 and a 200-day moving average price of $58.74. The company has a quick ratio of 0.60, a current ratio of 0.81 and a debt-to-equity ratio of 0.80. The stock has a market cap of $84.03 billion, a P/E ratio of 18.21, a PEG ratio of 0.98 and a beta of 0.57. CVS Health has a fifty-two week low of $43.56 and a fifty-two week high of $71.45.

CVS Health (NYSE:CVS - Get Free Report) last announced its quarterly earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.89 by $0.30. CVS Health had a net margin of 1.24% and a return on equity of 9.11%.

Institutional Trading of CVS Health

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Dodge & Cox raised its stake in CVS Health by 11.2% during the 4th quarter. Dodge & Cox now owns 70,105,899 shares of the pharmacy operator's stock valued at $3,147,054,000 after purchasing an additional 7,075,209 shares during the period. Capital World Investors lifted its stake in CVS Health by 26.6% in the fourth quarter. Capital World Investors now owns 61,039,777 shares of the pharmacy operator's stock valued at $2,739,927,000 after acquiring an additional 12,819,148 shares during the last quarter. Geode Capital Management LLC boosted its holdings in CVS Health by 2.6% in the fourth quarter. Geode Capital Management LLC now owns 27,051,540 shares of the pharmacy operator's stock worth $1,211,582,000 after purchasing an additional 689,867 shares in the last quarter. Capital International Investors increased its holdings in shares of CVS Health by 4.8% during the 4th quarter. Capital International Investors now owns 26,666,401 shares of the pharmacy operator's stock valued at $1,196,989,000 after acquiring an additional 1,212,126 shares during the last quarter. Finally, Pzena Investment Management LLC raised its position in shares of CVS Health by 49.3% in the fourth quarter. Pzena Investment Management LLC now owns 19,610,579 shares of the pharmacy operator's stock valued at $880,319,000 after purchasing an additional 6,475,271 shares during the period. Institutional investors and hedge funds own 80.66% of the company's stock.

Insider Activity

In related news, Director Michael F. Mahoney bought 30,000 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The shares were acquired at an average cost of $66.70 per share, for a total transaction of $2,001,000.00. Following the acquisition, the director now directly owns 39,356 shares of the company's stock, valued at $2,625,045.20. The trade was a 320.65 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, SVP James David Clark sold 7,513 shares of the company's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total value of $498,487.55. Following the sale, the senior vice president now directly owns 8,394 shares of the company's stock, valued at approximately $556,941.90. This represents a 47.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.22% of the company's stock.

CVS Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, May 1st. Shareholders of record on Tuesday, April 22nd will be given a dividend of $0.665 per share. The ex-dividend date of this dividend is Tuesday, April 22nd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.99%. CVS Health's dividend payout ratio (DPR) is 72.68%.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.